Intermediate Skeletal Muscle Cells occupy a significant place in the spectrum of muscle fiber types, standing between the fast-twitch (Type II) and slow-twitch (Type I) muscle fibers. These cells exhibit characteristics that share features of both fast and slow fibers, making them adaptable to various physiological demands. Intermediate fibers are characterized by a moderate contraction speed and a balance between endurance and strength capabilities. They contain a mix of myosin heavy chain isoforms, allowing for a more versatile performance. These cells are particularly prevalent in muscles that require a combination of endurance and strength, such as certain postural muscles. The metabolic profile of intermediate muscle cells falls between that of fast and slow fibers, relying on both aerobic and anaerobic pathways. The plasticity of these cells allows them to undergo transformation in response to specific stimuli, adapting to changes in workload or exercise patterns. This adaptability underscores the importance of intermediate muscle fibers in maintaining overall muscle function and performance. Understanding the characteristics and functions of these cells is vital for athletes, physiologists, and clinicians, as it provides insights into muscle physiology, training strategies, and the rehabilitation of muscle-related conditions.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States